Bhoj Lab

Research focus

NIH R01 · 2025

Selective B Cell Depletion Using Engineered T Cells As A Curative Treatment For Acquired Thrombotic Thrombocytopenic Purpura

Project Summary Immune thrombotic thrombocytopenic purpura (iTTP) is a life-threatening thrombotic microangiopathy characterized by thrombosis due to dysregulated platelet activation. iTTP results from autoantibodies directed against ADAMTS13, a plasma protease that regulates platelet activation via cleavage of von Willebrand Factor (vWF) multimers. Autoantibodies bind to and reduce ADAMTS13 activity resulting in ultralarge-vWF multimers that induce inappropriate platelet activation and microvascular thrombi leading to anemia and tissue ischemia with end-organ damage. Current therapeutic approaches oJer transient benefit and comprise daily plasma exchange therapy with or without the addition…

From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.